NCT07169981CompletedPhase 2
Effect of Empagliflozin 10 vs 25 mg on LV Remodeling in Diabetic Patients With Anterior STEMI With Reduced LVEF
Effect of Empagliflozin 10 vs 25 mg on LV Remodeling in Diabetic Patients With Anterior STEMI With Reduced LVEF Who Underwent Primary PCI
Source: ClinicalTrials.gov · Last updated 12 Sept 2025
Brief summary (registry, in English)
This study is investigating how the medication Empagliflozin affects the heart's structure and function in patients with heart disease. Empagliflozin is already used to treat diabetes and heart conditions, and this research aims to see if it can help improve heart remodeling, which may lead to better heart health and quality of life. Participants will receive the medication and have regular check-ups to monitor their progress. The study is carefully designed to ensure participant safety. If you have heart disease and want to learn more, please contact (hany\).
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (actual)
- First submitted
- 20 Aug 2025
- Start date
- 12 Jul 2023
- Primary completion date
- 23 Feb 2025
- Lead sponsor
- Ain Shams University
- Diseases
- Heart failure
- NCT number
- NCT07169981
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 200
- From 12 Jul 2023 to the primary completion date, 23 Feb 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients having valvular heart diseases.
- Patients having renal impairment.
Other
- patients who did not undergo primary PCI, those treated medically or had thrombolysis
- Non diabetic patient.
- Diabetic patient already on SGLTi
- STEMIs other than anterior.
- NSTEMI patients.
- Patients with LV myopathies of non-ischemic origin.
Who the study is looking for
- Diabetic patients with anterior STEMI with reduced LVEF who underwent PPCI with successful revascularization and resulting into TIMI III flow and who are receiving SGLTi for the first time.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ain Shams University Hospitals Coordinator of this site? Confirm its status | Cairo | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.